Form 4: UroGen Pharma Director Acquires Stock Options
SEC Form 4 Filing
Director Daniel George Wildman acquired stock options for 10,000 UroGen Pharma Ltd. shares on August 6, 2024.
Summary
- On August 6, 2024, Daniel George Wildman, a director of UroGen Pharma Ltd., acquired stock options for 10,000 ordinary shares.
- The exercise price of the stock options is $15.16.
- The options vest in equal quarterly installments over one year, contingent upon the director's continuous service.
- The expiration date for the options is August 6, 2034.
- Following the transaction, Wildman directly owns 10,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of a director's stock option grant, which is a common practice in publicly traded companies to align the interests of directors with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 08/06/2024 | Date of the stock option transaction. |
| 08/06/2034 | Expiration date of the stock options. |
| 08/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.